What's in Viatris Inc.'s pipeline?

Viatris Inc. has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Viatris Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Advanz, Azurity, Cephalon, Fera Pharms.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/viatris.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Viatris Inc. — Portfolio Competitive Intelligence Brief

Viatris Inc. (VTRS) pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

VTRS (NASDAQ) 2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cardura	DOXAZOSIN	marketed	alpha-Adrenergic Blocker	Alpha-1B adrenergic receptor	Cardiovascular	1990-01-01
Phenytoin Sodium	PHENYTOIN	marketed	Anti-epileptic Agent	Sodium channel protein type 2 subunit alpha	Neuroscience	1953-01-01

Therapeutic area mix

Cardiovascular · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Advanz · 1 shared drug class
Azurity · 1 shared drug class
Cephalon · 1 shared drug class
Fera Pharms · 1 shared drug class
Novartis · 1 shared drug class
· 1 shared drug class
Recordati · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Viatris Inc.:

Cite this brief

Drug Landscape (2026). Viatris Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/viatris. Accessed 2026-05-14.